No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Zealand Pharma shares surged on Wednesday as it announced a collaboration with Roche on the sale of rights to an obesity therapy in a deal worth up to $5.3bn.
The Swiss pharma giant will pay its Danish counterpart $1.65bn in cash up front and a further $1.2bn in development milestones when late-stage trials begin with a further $2.4bn up for grabs if sales targets are hit.
The two companies will co-develop and co-commercialise in Europe and the US Zealand's petrelintide and combination products with the drug, including a fixed-dose combination product of petrelintide and Roche's CT-388. Roche will be responsible for commercial manufacturing and supply.
Reporting by Frank Prenesti for Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.